UroGen Pharma (URGN) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $34.56, -5.60% vs the prior close of $36.61.
- Volume 1.05M shares, 1.2x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
URGN slides 5.6% to $34.56, a 3-month low. Closed at $34.56, -5.60% vs the prior close of $36.61. Day range $34.26–$36.91, opened at $36.35.
URGN daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — URGN slides 5.6% to $34.56, a 3-month low
- Closed at $34.56, -5.60% vs the prior close of $36.61. Day range $34.26–$36.91, opened at $36.35.
- Volume was 1.05M shares, 1.2x its 50-day average of 906.15K.
- Price is -20.0% vs its 50-day average ($43.21) and +12.6% vs its 200-day average ($30.69).
- 52-week range $16.36–$50.81; today's close sits at 53% of that range, 32.0% below the 52-week high.
Oct 15, 2026 — URGN ends flat (+0.1%) to $36.61
- Closed at $36.61, +0.08% vs the prior close of $36.58. Day range $36.27–$38.37, opened at $37.04.
- Volume was 636.50K shares, 0.7x its 50-day average of 943.04K.
- Price is -15.7% vs its 50-day average ($43.44) and +19.5% vs its 200-day average ($30.63).
- 52-week range $16.36–$50.81; today's close sits at 59% of that range, 27.9% below the 52-week high.
Oct 14, 2026 — URGN slides 4.4% to $36.58, a 3-month low
- Closed at $36.58, -4.39% vs the prior close of $38.26. Day range $36.44–$39.09, opened at $37.96.
- Volume was 1.08M shares, 1.2x its 50-day average of 936.13K.
- Price is -16.2% vs its 50-day average ($43.63) and +19.7% vs its 200-day average ($30.56).
- 52-week range $16.27–$50.81; today's close sits at 59% of that range, 28.0% below the 52-week high.
Oct 13, 2026 — URGN ends flat (-0.1%) to $38.26
- Closed at $38.26, -0.05% vs the prior close of $38.28. Day range $37.30–$38.84, opened at $37.82.
- Volume was 759.90K shares, 0.8x its 50-day average of 940.23K.
- Price is -12.4% vs its 50-day average ($43.70) and +25.5% vs its 200-day average ($30.49).
- 52-week range $16.18–$50.81; today's close sits at 64% of that range, 24.7% below the 52-week high.
Oct 12, 2026 — URGN jumps 3.9% to $38.28
- Closed at $38.28, +3.94% vs the prior close of $36.83. Day range $36.20–$38.31, opened at $36.97.
- Volume was 531.00K shares, 0.6x its 50-day average of 945.90K — lighter than usual.
- Price is -12.4% vs its 50-day average ($43.71) and +25.8% vs its 200-day average ($30.42).
- 52-week range $15.86–$50.81; today's close sits at 64% of that range, 24.7% below the 52-week high.
Oct 9, 2026 — URGN dips 0.4% to $36.83, a 3-month low on 4.4x normal volume
- Closed at $36.83, -0.41% vs the prior close of $36.98. Day range $36.69–$38.11, opened at $36.97.
- Volume was 3.90M shares, 4.4x its 50-day average of 883.57K — unusually heavy trading.
- Price is -15.7% vs its 50-day average ($43.70) and +21.4% vs its 200-day average ($30.35).
- 52-week range $15.86–$50.81; today's close sits at 60% of that range, 27.5% below the 52-week high.
- That makes 4 straight losses.
Oct 8, 2026 — URGN slides 9.1% to $36.98, a 3-month low on 2.4x normal volume
- Closed at $36.98, -9.14% vs the prior close of $40.70. Day range $34.18–$40.05, opened at $39.93.
- Volume was 2.02M shares, 2.4x its 50-day average of 849.59K — unusually heavy trading.
- Price is -15.6% vs its 50-day average ($43.79) and +22.1% vs its 200-day average ($30.28).
- 52-week range $15.86–$50.81; today's close sits at 60% of that range, 27.2% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — URGN dips 1.8% to $40.70
- Closed at $40.70, -1.76% vs the prior close of $41.43. Day range $40.64–$41.93, opened at $40.70.
- Volume was 486.20K shares, 0.6x its 50-day average of 847.69K — lighter than usual.
- Price is -7.2% vs its 50-day average ($43.86) and +34.7% vs its 200-day average ($30.21).
- 52-week range $15.86–$50.81; today's close sits at 71% of that range, 19.9% below the 52-week high.
Oct 6, 2026 — URGN slides 3.2% to $41.43
- Closed at $41.43, -3.16% vs the prior close of $42.78. Day range $41.10–$43.54, opened at $43.24.
- Volume was 764.40K shares, 0.9x its 50-day average of 842.74K.
- Price is -5.5% vs its 50-day average ($43.86) and +37.6% vs its 200-day average ($30.12).
- 52-week range $15.86–$50.81; today's close sits at 73% of that range, 18.5% below the 52-week high.
Oct 5, 2026 — URGN jumps 3.3% to $42.78
- Closed at $42.78, +3.33% vs the prior close of $41.40. Day range $40.50–$42.90, opened at $41.38.
- Volume was 1.28M shares, 1.5x its 50-day average of 825.64K.
- Price is -2.5% vs its 50-day average ($43.86) and +42.5% vs its 200-day average ($30.02).
- 52-week range $15.86–$50.81; today's close sits at 77% of that range, 15.8% below the 52-week high.
Oct 2, 2026 — URGN rises 2.1% to $41.40
- Closed at $41.40, +2.10% vs the prior close of $40.55. Day range $40.05–$41.82, opened at $40.93.
- Volume was 597.60K shares, 0.7x its 50-day average of 823.58K.
- Price is -5.5% vs its 50-day average ($43.83) and +38.3% vs its 200-day average ($29.92).
- 52-week range $15.86–$50.81; today's close sits at 73% of that range, 18.5% below the 52-week high.
URGN latest news & SEC filings
Every SEC filing by or about URGN in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Degnan Chris converted options/RSUs into 4,483 shares on Oct 8, 2026; now holds 6,763
- Degnan Chris sold 2,202 shares at $36.69 (≈$80.79K) on Oct 8, 2026; now holds 4,561
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 9, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Schoenberg Mark sold 871 shares at $42.92 (≈$37.38K) on Sep 8, 2026
- Schoenberg Mark sold 871 shares at $42.92 (≈$37.38K) on Sep 8, 2026
- Schoenberg Mark sold 871 shares at $42.92 (≈$37.38K) on Sep 8, 2026
- Schoenberg Mark sold 871 shares at $42.92 (≈$37.38K) on Sep 8, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Smith Jason Drew sold 1,519 shares at $42.54 (≈$64.62K) on Sep 8, 2026
- Smith Jason Drew sold 1,519 shares at $42.54 (≈$64.62K) on Sep 8, 2026
- Smith Jason Drew sold 1,519 shares at $42.54 (≈$64.62K) on Sep 8, 2026
- Smith Jason Drew sold 1,519 shares at $42.54 (≈$64.62K) on Sep 8, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 9, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 9, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 20, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 12, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 5, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $72.46M (prior year $24.21M) (+199.2% vs Jun 30, 2025)
- Net income: -$14.35M (prior year -$49.94M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.28 (prior year -$1.05) (loss narrowed vs Jun 30, 2025)
Aug 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jun 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 3.03 — Change to shareholder rights.
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 5.07 — Reported shareholder vote results.
Things to know before you trade URGN
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: May 6, 2026, Mar 2, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.09% (largest 9.1%).
- Liquidity: about 1.00M shares (≈$34.68M) trade per day on average.
- 52-week position: $34.56 vs a range of $16.36–$50.81 (53% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Jason Drew Smith sold 1,519 shares on Sep 8, 2026.
- Latest filings: 8-K Aug 20, 2026; 10-Q Aug 5, 2026; 8-K Aug 5, 2026.
- Share count: 48.88M shares outstanding (Jul 28, 2026), +5.7% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
URGN market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 36.35 | 36.91 | 34.26 | 34.56 | 1.05M |
| Oct 15, 2026 | 37.04 | 38.37 | 36.27 | 36.61 | 636.50K |
| Oct 14, 2026 | 37.96 | 39.09 | 36.44 | 36.58 | 1.08M |
| Oct 13, 2026 | 37.82 | 38.84 | 37.30 | 38.26 | 759.90K |
| Oct 12, 2026 | 36.97 | 38.31 | 36.20 | 38.28 | 531.00K |
| Oct 9, 2026 | 36.97 | 38.11 | 36.69 | 36.83 | 3.90M |
| Oct 8, 2026 | 39.93 | 40.05 | 34.18 | 36.98 | 2.02M |
| Oct 7, 2026 | 40.70 | 41.93 | 40.64 | 40.70 | 486.20K |
| Oct 6, 2026 | 43.24 | 43.54 | 41.10 | 41.43 | 764.40K |
| Oct 5, 2026 | 41.38 | 42.90 | 40.50 | 42.78 | 1.28M |
| Oct 2, 2026 | 40.93 | 41.82 | 40.05 | 41.40 | 597.60K |
| Oct 1, 2026 | 40.63 | 41.26 | 40.10 | 40.55 | 624.60K |
| Sep 30, 2026 | 40.72 | 41.10 | 40.08 | 40.63 | 641.40K |
| Sep 29, 2026 | 40.50 | 41.69 | 39.75 | 40.45 | 642.80K |
| Sep 28, 2026 | 40.74 | 41.33 | 40.32 | 40.90 | 1.17M |
| Sep 25, 2026 | 41.23 | 41.78 | 40.65 | 41.35 | 655.30K |
| Sep 24, 2026 | 41.24 | 41.62 | 39.90 | 41.23 | 1.07M |
| Sep 23, 2026 | 42.72 | 42.72 | 39.72 | 41.63 | 1.30M |
| Sep 22, 2026 | 43.58 | 44.08 | 42.60 | 42.76 | 394.60K |
| Sep 21, 2026 | 44.00 | 44.00 | 42.53 | 43.20 | 482.40K |
About UroGen Pharma
UroGen Pharma (URGN) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in RA'ANANA, Israel. State of incorporation: Israel. Fiscal year ends December 31. SEC CIK 1668243.
URGN board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Cynthia M Butitta | Director | Jun 24, 2026 |
| Arie Belldegrun | Director | Jun 24, 2026 |
| Stuart Holden | Director | Jun 24, 2026 |
| James A. Jr. Robinson | Director | Aug 28, 2026 |
| Leana Wen | Director | Jun 24, 2026 |
| Daniel George Wildman | Director | Jun 24, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Elizabeth A. Barrett | Chief Executive Officer | Feb 19, 2026 |
| Chris Degnan | Chief Financial Officer | Feb 3, 2026 |
| Mark Schoenberg | Chief Medical Officer | Sep 9, 2026 |
| Jason Drew Smith | General Counsel | Sep 9, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 8, 2026 | Jason Drew Smith | Sale | 1,519 | $42.54 |
| Sep 8, 2026 | Jason Drew Smith | Sale | 1,519 | $42.54 |
| Sep 8, 2026 | Jason Drew Smith | Sale | 1,519 | $42.54 |
| Sep 8, 2026 | Jason Drew Smith | Sale | 1,519 | $42.54 |
| Sep 8, 2026 | Mark Schoenberg | Sale | 871 | $42.92 |
| Sep 8, 2026 | Mark Schoenberg | Sale | 871 | $42.92 |
| Sep 8, 2026 | Mark Schoenberg | Sale | 871 | $42.92 |
| Sep 8, 2026 | Mark Schoenberg | Sale | 871 | $42.92 |
| Aug 20, 2026 | Mark Schoenberg | Sale | 60,677 | $47.05 |
| Aug 20, 2026 | Mark Schoenberg | Sale | 60,677 | $47.05 |
| Aug 20, 2026 | Mark Schoenberg | Sale | 60,677 | $47.05 |
| Aug 20, 2026 | Mark Schoenberg | Sale | 60,677 | $47.05 |
| Jul 9, 2026 | Mark Schoenberg | Sale | 10,000 | $40.00 |
| Jul 9, 2026 | Mark Schoenberg | Sale | 10,000 | $40.00 |
| Jul 9, 2026 | Mark Schoenberg | Sale | 10,000 | $40.00 |
URGN financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $109.79M | $-153.49M | -3.19 | $-162.44M |
| Dec 31, 2024 | $90.40M | $-126.87M | -2.96 | $-96.77M |
| Dec 31, 2023 | $82.71M | $-102.24M | -3.55 | $-76.38M |
| Dec 31, 2022 | $64.36M | $-109.78M | -4.81 | $-87.56M |
| Dec 31, 2021 | $48.04M | $-110.82M | -4.96 | $-84.89M |
Latest balance sheet: total assets $252.59M, total liabilities $384.99M, cash $79.13M (as of Jun 30, 2026).
URGN earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $46.43 |
| May 6, 2026 | 8-K Item 2.02 (results) | $26.25 |
| Mar 2, 2026 | 8-K Item 2.02 (results) | $19.02 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $23.54 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $18.59 |
| May 12, 2025 | 8-K Item 2.02 (results) | $11.14 |
| Mar 10, 2025 | 8-K Item 2.02 (results) | $9.92 |
| Nov 6, 2024 | 8-K Item 2.02 (results) | $12.24 |
| Aug 13, 2024 | 8-K Item 2.02 (results) | — |
| May 13, 2024 | 8-K Item 2.02 (results) | — |
| Mar 14, 2024 | 8-K Item 2.02 (results) | — |
| Nov 14, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on URGN
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.